Keywords: Novartis, Vaccines, EU Commission, R&D funding
EU Commission clears 23 million-euro R&D aid to Novartis Italy for vaccines in developing countries
Article | 08 May 2012
The European Commission has concluded that 23 million euros ($30.2 million) public funding, which Italy intends to grant to Novartis Vaccines & ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
